Maurie Markman, MD

Articles

Oncologic Supportive Care Is Absolutely Critical—But How Do We Define It?

June 7th 2024

Defining the goals of a clinical team within a cancer program or oncology practice group, where the focus will be on maximizing QOL, may be difficult.

Improved Survival in Randomized Trials: A Meaningful Outcome but Increasingly Difficult to Demonstrate

May 9th 2024

Maurie Markman, MD, expands on the debate regarding the appropriate primary outcome end point for improved clinical benefit in a trial.

The Critical Nature of Decision-Making in the Development of Phase 3 Clinical Trials

April 12th 2024

Randomized trials are widely recognized to play a pivotal role in the decision-making associated with the establishment of clinical guidelines.

Is It Time to Address the Fiscal Reality of the Cancer Care Model and Consider Alternatives?

March 25th 2024

Two items in the medical world should send chills down the spines of those considering the possible financial future of oncology care in the United States.

Phase 3 Randomized Trials: Expanding Clinically Meaningful Analysis Beyond the Stated Goals

February 9th 2024

The foundation of physician recommendations and medical/regulatory policy will be guided by the outcomes of published clinical research.

Actionable Molecular Findings: Increasingly Clinically Relevant but Also Increasingly Complex

January 31st 2024

Maurie Markman, MD, discusses the need for a decision support strategy to assist oncologists in treatment selection for patients with actionable mutations.

Outdated Terminology in Oncology: Is It Finally Time to Reassess?

January 23rd 2024

The absence of clearly articulated definitions and transparency related to how clinical trial outcomes are interpreted and utilized raise concerns.

Public Trust in Science and the Future of Cancer Care Is Crucial

January 12th 2024

Maurie Markman, MD, details how public trust is critical in the future of cancer care, diving into what leads to mistrust and misinformation today.

When Will We Acknowledge Information Overload in Oncology?

January 2nd 2024

The goal in highlighting this development is to attempt to raise awareness of the critical issue of information overload and the need for multiple involved parties to actively and aggressively search for appropriate, effective, and fiscally rational solutions.

Markman Reflects on Key Advances Made in 2023 in the Realm of Gynecologic Cancers and Beyond

December 27th 2023

Maurie Markman, MD, highlights inroads made with immunotherapy, antibody-dependent cytotoxic agents, and molecular testing across oncology.

Patient and Family Interpretations of the Language of Cancer Care

December 1st 2023

This commentary examines the use of words and expressions in the oncology domain and the implications of different interpretations by patients and their families from professionals employing this language, including academic authors and members of their clinical teams.

Dr Markman on Pragmatic Clinical Trial Designs in Ovarian Cancer

November 9th 2023

Maurie Markman, MD, discusses the importance of designing clinical trials for patients with ovarian cancer that are based on real-world data and consider the increasing complexity of treatment sequencing in this disease.

Reality Takes a Back Seat to Rhetoric Used in Objective Assessments of Cancer Treatment

November 6th 2023

It is time for society to address the critical nature of our current unsustainable oncology pharmaceutical marketplace, and it is also essential that whatever solutions are proposed and implemented do not incorporate inappropriate labeling of outcomes that negate meaningful measures of clinical benefit.

The Bleak Fiscal Implications of Advanced Cancer as a Chronic Illness

October 13th 2023

Maurie Markman, MD, highlights the rather profound fiscal implications of the combined effect of 2 quite different but closely related components of the rapidly evolving cancer treatment paradigm.

Generic Drug Shortage of Platinum Agents in Ovarian Cancer Sends Cautionary Signal

September 6th 2023

The well-publicized severe shortage of vitally important generic antineoplastic agents has highlighted a serious misalignment in the existing market-based and regulatory environment that permitted such an extraordinary situation to develop without meaningful resolution.

Unresolved Issues in Antineoplastic Drug Therapy: Is It Finally Time to Address?

August 14th 2023

Several articles featured in a recent issue of the highly respected publication the Medical Letter on Drugs and Therapeutics highlight themes across drug development that are relevant within the broad antineoplastic arena. The topics range from appropriate control arms in randomized clinical trials to sponsorship of trials to the rationale for developing novel agents when suitable, cost-effective biosimilar and generic products are available.

Evaluating Toxicities of Antineoplastic Drug Therapeutics: Is It Time for a Critical Review?

July 24th 2023

An evaluation of the utility of a cancer therapeutic in a clinical trial is determined through metrics that define 2 distinctive features of an antineoplastic strategy: efficacy and toxicity. Although that may be an oversimplification, the aim of such therapy is to improve clinical outcomes.

Interpreting Clinical Trial Data Is Not as Simple as It May Seem

July 10th 2023

In our fast-moving world where a report of a clinically important trial finding may be simply a 60-second sound bite for both lay and medical communities, it is critical that great care must be taken that reported conclusions are understandable to all, not just the statisticians.

Rapid Accelerating Changes in Cancer Management Through the Lens of Ovarian Cancer

June 13th 2023

Maurie Markman, MD, discusses changes in cancer management as seen in ovarian cancer.

The Placebo: A Controversial Element of Randomized Cancer Clinical Trials

May 19th 2023

The potential effectiveness of employing placebo in cancer clinical investigation is not difficult to appreciate, but the use of this approach has been, and continues to be, controversial.